Het Hollandsch Effectenkantoor | Mogelijk bod op Biogen

Nieuwsbrief

U kunt onze nieuwsbrief kosteloos aanvragen.

11,3% Immovest Emsland IV

Interessant woningfonds,
rente 8,5% p/j,
met bonusuitkering

Lees verder »

Winkelhart Lelystad CV nu wel interessant

Sterk verbeterde propositie winkel CV

Lees verder »

Degelijk winkelfonds Rijnvast

Nieuw winkelfonds van Rijnvast met kwartaalbetaling en winstdeling

Lees verder »

Overzicht emissies

Welke vastgoedfondsen zijn in emissie? een overzicht!

Lees verder »


	12 oktober 2007 Speculation over Biogen's future began Friday (12 oktober 2007) when Biogen, the maker of multiple-sclerosis drugs said it was evaluating a possible sale and had appointed bankers to assess interest. Among those who did is activist shareholder Carl Icahn, who made an offer at a potential price of at least $23 billion, The Wall Street Journal reported. As analysts weigh possible suitors and valuations, investors swooped on the stock. Biogen closed at $82.51, up almost 19%. That values the company at about $23.7 billion.